Circio Holding ASA: Issuance of restricted stock units (RSUs) to board member

Oslo, 11 May 2026: Reference is made to the annual general meeting of Circio Holding ASA (the "Company") on 8 May, 2026 (the "AGM") where the election of members to the board of directors was made according to the proposal by the nomination committee.

At the AGM, the board of directors was authorized to extend the Company's restricted stock unit ("RSU") program and to issue RSUs to directors of the board as an alternative to cash compensation. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.60 per share (corresponding to the nominal value of the shares) subject to satisfaction of the applicable vesting conditions.

If the board members choose to receive the board remuneration in RSUs they must elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the compensation in cash and 1/3 in RSUs.

The number of RSUs is calculated on the basis of a board remuneration of NOK 575 000 for the chairperson of the board, NOK 350,000 for other board members and 180,000 for deputy members of the board, divided by the market price of the Company's shares calculated as the volume weighted average share price for the 10 trading days prior to the AGM, on 8 May 2026, being NOK 8.7966 per share.

* Robert Burns, deputy member of the board of directors, has resolved to receive 1/3 of the board remuneration, as determined by the Company's annual general meeting in 2026, in the form of RSUs and the board of directors has resolved to issue 6,821 RSUs to Robert Burns. Robert Burns holds 6,821 RSUs, no options and 100,000 shares in the Company.

Please see the attached notifications of trade for information regarding the issuance of RSUs to the primary insiders.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com

Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com

About Circio Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.